Tscan Therapeutics Stock EBITDA
| TCRX Stock | USD 1.59 0.04 2.58% |
Tscan Therapeutics fundamentals help investors to digest information that contributes to Tscan Therapeutics' financial success or failures. It also enables traders to predict the movement of Tscan Stock. The fundamental analysis module provides a way to measure Tscan Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tscan Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -119.7 M | -113.8 M |
Tscan | EBITDA |
Tscan Therapeutics Company EBITDA Analysis
Tscan Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Tscan Therapeutics EBITDA | (119.74 M) |
Most of Tscan Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tscan Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Tscan EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Tscan Therapeutics is extremely important. It helps to project a fair market value of Tscan Stock properly, considering its historical fundamentals such as EBITDA. Since Tscan Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tscan Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tscan Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Tscan Ebitda
According to the company disclosure, Tscan Therapeutics reported earnings before interest,tax, depreciation and amortization of (119.74 Million). This is 113.65% lower than that of the Biotechnology sector and 219.55% lower than that of the Health Care industry. The ebitda for all United States stocks is 103.07% higher than that of the company.
Tscan EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tscan Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tscan Therapeutics could also be used in its relative valuation, which is a method of valuing Tscan Therapeutics by comparing valuation metrics of similar companies.Tscan Therapeutics is currently under evaluation in ebitda category among its peers.
Tscan Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Tscan Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Tscan Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Tscan Therapeutics' value.| Shares | Aberdeen Group Plc | 2024-12-31 | 883.7 K | State Street Corp | 2024-12-31 | 800.9 K | Dc Funds, Lp | 2024-12-31 | 630 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 412.9 K | Northern Trust Corp | 2024-12-31 | 322.1 K | Dimensional Fund Advisors, Inc. | 2024-12-31 | 280 K | Tocqueville Asset Management L.p. | 2024-12-31 | 260.9 K | Goldman Sachs Group Inc | 2024-12-31 | 160.7 K | Bank Of America Corp | 2024-12-31 | 150.1 K | Ecor1 Capital, Llc | 2024-12-31 | 5 M | Blackrock Inc | 2024-12-31 | 5 M |
Tscan Fundamentals
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.26 | ||||
| Operating Margin | (55.21) % | ||||
| Current Valuation | (105.01 M) | ||||
| Shares Outstanding | 52.31 M | ||||
| Shares Owned By Insiders | 0.82 % | ||||
| Shares Owned By Institutions | 90.58 % | ||||
| Number Of Shares Shorted | 2 M | ||||
| Price To Earning | 23.45 X | ||||
| Price To Book | 0.36 X | ||||
| Price To Sales | 31.15 X | ||||
| Revenue | 2.82 M | ||||
| Gross Profit | (2.03 M) | ||||
| EBITDA | (119.74 M) | ||||
| Net Income | (127.5 M) | ||||
| Cash And Equivalents | 125.6 M | ||||
| Cash Per Share | 5.22 X | ||||
| Total Debt | 65.31 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 7.53 X | ||||
| Book Value Per Share | 4.26 X | ||||
| Cash Flow From Operations | (110.82 M) | ||||
| Short Ratio | 5.80 X | ||||
| Earnings Per Share | (1.14) X | ||||
| Target Price | 9.71 | ||||
| Number Of Employees | 194 | ||||
| Beta | 0.91 | ||||
| Market Capitalization | 87.72 M | ||||
| Total Asset | 371.12 M | ||||
| Retained Earnings | (375.1 M) | ||||
| Working Capital | 256.77 M | ||||
| Net Asset | 371.12 M |
About Tscan Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tscan Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tscan Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tscan Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Tscan Stock Analysis
When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.